ArticleFrontiers in public health2023
Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The shifting burden of tracheal, bronchus and lung cancer in ageing Asia: structural drivers and projections to 2050.Annals of medicine · 2026Article
- GRP78 Drives NSCLC Stemness and EMT via a SIX1/β-Catenin Signaling Axis.Drug development research · 2026Article
- A multimodal radiomics model to predict disease-free survival in resected non-small cell lung cancer: integrating clinicopathology, dual-energy CT, and deep learning features.Journal of thoracic disease · 2026Article
- Construction of a postoperative disease-free survival prediction model for non-small cell lung cancer patients based on dual-energy computed tomography parameters and blood inflammatory indicators.Translational cancer research · 2026Article
- Pulmonary Drug Delivery for Infectious Diseases: Cutting-Edge Formulations and Manufacturing Technologies.Pharmaceutics · 2026Review
- Burden of tracheal, bronchus, and lung cancer based on GBD 2021.Discover oncology · 2026Article
- Article
- Analysis and prediction of the burden of lung cancer attributable to diet low in fruits in China and the global from 1990 to 2021.PloS one · 2026Article
- Aging and lung diseases: Unraveling mechanisms and therapeutic targets.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Comparative Evaluation of Explainable Machine Learning Versus Linear Regression for Predicting County-Level Lung Cancer Mortality Rate in the United States.JCO clinical cancer informatics · 2025Article
- Article
- Disease burden and changing trend of tracheal, bronchus, and lung cancer attributable to tobacco, globally and in China, the USA, the Russian Federation, and India, 1990-2021.Journal of thoracic disease · 2025Article
- A population-based nomogram for prognostic assessment in advanced lung cancer following progression with immune checkpoint inhibitor.Journal of thoracic disease · 2025Article
- Clinical features and prognostic nomogram development for cancer-specific death in patients with dual primary lung cancer: a population-based study from SEER database.Journal of cardiothoracic surgery · 2025Article
- Recent advancements in lung cancer research: a narrative review.Translational lung cancer research · 2025Review
- Article
- Global burden of lung cancer attributable to metabolic and dietary risk factors: an overview of 3 decades and forecasted trends to 2036.Frontiers in nutrition · 2025Article
- Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer.Frontiers in pharmacology · 2025Review
- Changing trends in lung cancer disease burden between China and Australia from 1990 to 2019 and its predictions.Thoracic cancer · 2025Article
- Incidence and survival of Lung Cancer: A retrospective population-based cohort (Monastir, Tunisia: 2002-2022).PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the effects of demographic drivers on lung cancer mortality trends is critical for lung cancer control. We have examined the drivers of lung cancer mortality at the global, regional, and national levels. Methods: Data on lung cancer death and mortality were extracted from the Global Burden of Disease (GBD) 2019. Estimated annual percentage change (EAPC) in the age-standardized mortality rate (ASMR) for lung cancer and all-cause mortality were calculated to measure temporal trends in lung cancer from 1990 to 2019. Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality. Results: Despite a non-significant decrease in ASMR [EAPC = -0.31, 95% confidence interval (CI): -1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5-109.0%] between 1990 and 2019. This increase was due to the changes in the number of deaths attributable to population aging (59.6%), population growth (56.7%), and non-GBD risks (3.49%) compared with 1990 data. Conversely, the number of lung cancer deaths due to GBD risks decreased by 19.8%, mainly due to tobacco (-12.66%), occupational risks (-3.52%), and air pollution (-3.47%). More lung cancer deaths (1.83%) were observed in most regions, which were due to high fasting plasma glucose levels. The temporal trend of lung cancer ASMR and the patterns of demographic drivers varied by region and gender. Significant associations were observed between the contributions of population growth, GBD risks and non-GBD risks (negative), population aging (positive), and ASMR in 1990, the sociodemographic index (SDI), and the human development index (HDI) in 2019. Conclusion: Population aging and population growth increased global lung cancer deaths from 1990 to 2019, despite a decrease in age-specific lung cancer death rates due to GBD risks in most regions. A tailored strategy is needed to reduce the increasing burden of lung cancer due to outpacing demographic drivers of epidemiological change globally and in most regions, taking into account region- or gender-specific risk patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.